
WHY CONSIDER ENDOART®?

Demonstrated edema reduction

Published evidence reports sustained reductions in central corneal thickness, with improvements in corneal clarity, vision and pain.[1-4]


Plan with confidence

Three-year shelf life supports scheduling around patient needs – not donor-tissue availability.



COULD ENDOART® BE THE MISSING PIECE FOR YOUR PATIENTS?

DMEK, DSAEK and PKP are established treatments for chronic corneal edema. However, graft failure, limited donor tissue or certain ocular conditions can make further transplantation unsuitable, leading to a repeat-graft cycle.



EndoArt® provides an additional, donor-independent option when transplantation has failed, is unsuitable, or unavailable.

EyeYon MEDICAL


www.eye-yon.com

Rev.1.0

EndoArt®
Artificial Endothelial Layer


EXPANDING TREATMENT POSSIBILITIES FOR CHRONIC CORNEAL EDEMA

A donor-independent option when endothelial transplantation has failed, is unsuitable or unavailable.



DESIGNED FOR THE POSTERIOR CORNEA

EndoArt® is a thin, transparent, acellular synthetic implant designed to attach to the posterior cornea, reducing fluid entry into the central corneal stroma while leaving the peripheral cornea uncovered for fluid and nutrient exchange.



During the 30–40-minute procedure, it is inserted through a small incision, secured with at least one suture and supported by an air/gas bubble to promote attachment.

1,300+
IMPLANTATIONS WORLDWIDE

28+
PEER-REVIEWED ARTICLES

UP TO 7
YEARS' FOLLOW-UP

"EndoArt® … fills a large medical, surgical, and logistical gap for my patients with complex corneas who may not be suitable for further tissue transplantation."

Prof. David Lockington

"It's a different patient population that right now we're under-addressing or addressing with suboptimal solutions."

Prof. Sorcha Ní Dhubhghaill

CLINICAL EXPERIENCE SHOWS IMPROVEMENT IN CCT, VISION AND PAIN[4,5]

85% CCT IMPROVEMENT
Patients with improvement at 12 months

71% VISION IMPROVEMENT
Patients gaining ≥2 ETDRS lines of BCVA at 12 months

91% PAIN RELIEF
Patients with baseline pain reporting relief at 12 months

*Accumulated clinical-study and pre-market data, n=146; data on file. Individual outcomes may vary.

SAFETY[4]

No serious device-related adverse events or chronic inflammatory reactions were reported in 24 treated eyes during 12-month follow-up.

REFERENCES:

1. Fontana L, et al. Cornea. 2026;45:141–47.
2. Lapid-Gortzak R, van der Meulen I. Klinische Monatsblätter für Augenheilkunde. 2025;242:318–23.
3. Son HS, et al. Cornea. 2026;45:1012–18.
4. Daphna O, et al. Cornea. 2025;44:1240–47.
5. EyeYon Medical. Accumulated EndoArt clinical-study and pre-market outcomes at 12 months. Data on file.